Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H de Mulder

Showing results (101-110 of 137) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 1, 1995
High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary GroupM Brausi, W G Jones, S D Fosså, et al.
Urologic Oncology|January 14, 2011
The role of neoadjuvant or adjuvant chemotherapy for invasive bladder cancer Is there a benefit for survival or preserving the bladder?M Pavone-Macaluso, R R Hall, Y Hirao, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinomaP H de Mulder, F M Debruyne, M P Franssen, et al.
Cancer|November 15, 1994
Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complicationW H Kruit, K J Punt, S H Goey, et al.
Therapeutic Drug Monitoring|September 1, 1987
Propylene glycol pharmacokinetics and effects after intravenous infusion in humansP A Speth, T B Vree, N F Neilen, et al.
British Journal of Cancer|September 1, 1996
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanomaW H Kruit, C J Punt, S H Goey, et al.
Scandinavian Journal of Immunology|September 1, 1992
Effect of rIFN-gamma on antibody-mediated cytotoxicity via human monocyte IgG Fc receptor II (CD32)R C van Schie, H G Verstraten, W J Tax, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials GroupU Bruntsch, B Heinrich, S B Kaye, et al.
Anticancer Research|November 1, 1993
Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinomaW Den Otter, F W Hill, W R Klein, et al.
The Journal of Investigative Dermatology|February 1, 1984
Monocyte function is normal in quiescent psoriasisJ P Geerdink, P H de Mulder, M R Franzen, et al.
Pageof 14

Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|September 1, 1995
High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary GroupM Brausi, W G Jones, S D Fosså, et al.
Urologic Oncology|January 14, 2011
The role of neoadjuvant or adjuvant chemotherapy for invasive bladder cancer Is there a benefit for survival or preserving the bladder?M Pavone-Macaluso, R R Hall, Y Hirao, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinomaP H de Mulder, F M Debruyne, M P Franssen, et al.
Cancer|November 15, 1994
Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complicationW H Kruit, K J Punt, S H Goey, et al.
Therapeutic Drug Monitoring|September 1, 1987
Propylene glycol pharmacokinetics and effects after intravenous infusion in humansP A Speth, T B Vree, N F Neilen, et al.
British Journal of Cancer|September 1, 1996
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanomaW H Kruit, C J Punt, S H Goey, et al.
Scandinavian Journal of Immunology|September 1, 1992
Effect of rIFN-gamma on antibody-mediated cytotoxicity via human monocyte IgG Fc receptor II (CD32)R C van Schie, H G Verstraten, W J Tax, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials GroupU Bruntsch, B Heinrich, S B Kaye, et al.
Anticancer Research|November 1, 1993
Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinomaW Den Otter, F W Hill, W R Klein, et al.
The Journal of Investigative Dermatology|February 1, 1984
Monocyte function is normal in quiescent psoriasisJ P Geerdink, P H de Mulder, M R Franzen, et al.
Pageof 14